GARDEN CITY, N.Y., Oct. 02, 2024 — Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients, today announced entering a strategic partnership with Healthcare Links, a renowned healthcare advisory and contracting firm. This partnership is focused on expanding access to Beyond Air’s LungFit® PH system by streamlining entry into Group Purchasing Organizations (GPOs) and Integrated Delivery Networks (IDNs) across the United States.
Ken Murawski, President and Founder of Healthcare Links, commented, “We are thrilled to work with Beyond Air in introducing the LungFit PH system to our extensive network of progressive GPOs and IDNs. This technology not only enhances patient care but also significantly improves logistical efficiency for healthcare providers. It’s a game-changer, and we are eager to support its expansion across the healthcare continuum.”
The LungFit® PH system, a groundbreaking inhaled nitric oxide (NO) generator and delivery system, has been developed to treat patients with persistent pulmonary hypertension of the newborn (PPHN) and other associated respiratory conditions. The innovative technology allows for on-demand NO generation from ambient air, eliminating the need for cylinder storage, enhancing patient safety, and improving operational efficiencies for healthcare facilities.
With Healthcare Links’ expertise in facilitating relationships and contracts with GPOs and IDNs, this partnership will help fast-track the availability of LungFit PH to a larger network of hospitals and healthcare providers. By tapping into these critical distribution channels, Beyond Air aims to broaden the reach of its life-saving technology, ensuring that more patients, particularly vulnerable newborns, can benefit from this cutting-edge respiratory therapy.
“Our partnership with Healthcare Links marks a pivotal moment in our mission to make the LungFit PH system widely accessible to hospitals. We are confident that by leveraging Healthcare Links’ extensive knowledge of GPOs and IDNs, we will be able to more rapidly scale access for hospitals to our innovative NO delivery technology, addressing a critical need in respiratory care,” commented Steve Lisi, Chairman and Chief Executive Officer of Beyond Air.
The LungFit® PH system is approved for commercial use in the U.S. to treat term and near-term neonates with hypoxic respiratory failure. Through this partnership, Beyond Air and Healthcare Links are committed to reducing barriers to entry and simplifying the contracting process, ensuring that hospitals across the country can seamlessly integrate this advanced respiratory therapy into their patient care protocols.
As Beyond Air continues to innovate in the field of respiratory medicine, this collaboration represents a significant step in the company’s mission to deliver life-saving solutions to those who need them most.
About LungFit®*
Beyond Air’s LungFit is a cylinder-free, phasic flow generator and delivery system and has been designated as a medical device by the U.S. Food and Drug Administration (FDA). The ventilator compatible version of the device can generate NO from ambient air on demand for delivery to the lungs at concentrations ranging from 1 ppm to 80 ppm. The LungFit system could potentially replace large, high-pressure NO cylinders providing significant advantages in the hospital setting, including greatly reducing inventory and storage requirements, improving overall safety with the elimination of NO2 purging steps, and other benefits. LungFit can also deliver NO at concentrations at or above 80 ppm for potentially treating severe acute lung infections in the hospital setting (e.g. COVID-19, bronchiolitis) and chronic, refractory lung infections in the home setting (e.g. NTM). With the elimination of cylinders, Beyond Air intends to offer NO treatment in the home setting.
* Beyond Air’s LungFit PH is approved for commercial use only in the United States of America to treat term and near-term neonates with hypoxic respiratory failure. Beyond Air’s other LungFit systems are not approved for commercial use and are for investigational use only. Beyond Air is not suggesting NO use over 80 ppm or use at home.
About Nitric Oxide
Nitric Oxide is a powerful molecule, naturally synthesized in the human body, proven to play a critical role in a broad array of biological functions. In the airways, NO targets the vascular smooth muscle cells that surround the small resistance arteries in the lungs. Currently, exogenous inhaled NO is used in adult respiratory distress syndrome, post certain cardiac surgeries and persistent pulmonary hypertension of the newborn to treat hypoxemia. Additionally, NO is believed to play a key role in the innate immune system and in vitro studies suggest that NO possesses anti-microbial activity not only against common bacteria, including both gram-positive and gram-negative, but also against other diverse pathogens, including mycobacteria, viruses, fungi, yeast and parasites, and has the potential to eliminate multi-drug resistant strains.
About Beyond Air, Inc.
Beyond Air, Inc. (NASDAQ: XAIR) is a global leader in medical technology focused on developing transformative treatments for lung diseases. The company’s LungFit® platform is a revolutionary NO generation and delivery system aimed at treating a variety of respiratory conditions, from neonatal intensive care needs to adult respiratory distress. Beyond Air’s innovative, portable systems are designed to eliminate the need for NO storage and transportation, improving both patient safety and healthcare efficiency.
About Healthcare Links
Healthcare Links is a leading advisory and contracting firm that specializes in accelerating market access for healthcare products and services. With a vast network of GPOs, IDNs, and other healthcare purchasing entities, Healthcare Links provides manufacturers with critical insights and pathways to streamline market entry and enhance product distribution across the U.S. healthcare landscape.
For more information, please visit www.beyondair.net and www.healthcarelinks.net.
Forward Looking Statements
This press release contains “forward-looking statements” (as defined in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended). You can identify such forward-looking statements by the words “appears,” “expects,” “plans,” “anticipates,” “believes” “expects,” “intends,” “looks,” “projects,” “goal,” “assumes,” “targets” and similar expressions and/or the use of future tense or conditional constructions (such as “will,” “may,” “could,” “should” and the like) and by the fact that these statements do not relate strictly to historical or current matters. Rather, forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause actual results to differ materially from any future results expressed or implied by the forward-looking statements. These forward-looking statements are only predictions and reflect views as of the date they are made with respect to future events and financial performance. Many factors could cause actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including those related to the completion of the offering, risks related to the ability to raise additional capital; the timing and results of future pre-clinical studies and clinical trials; the potential that regulatory authorities, including the FDA and comparable non-U.S. regulatory authorities, may not grant or may delay approval for our product candidates; the approach to discover and develop novel drugs, which is unproven and may never lead to efficacious or marketable products; the ability to fund and the results of further pre-clinical studies and clinical trials of our product candidates; obtaining, maintaining and protecting intellectual property utilized by products; obtaining regulatory approval for products; competition from others using similar technology and others developing products for similar uses; dependence on collaborators; and other risks, which may, in part, be identified and described in the “Risk Factors” section of Beyond Air’s most recent Annual Report on Form 10-K and other of its filings with the Securities and Exchange Commission, all of which are available on Beyond Air’s website. Beyond Air undertakes no obligation to update, and have no policy of updating or revising, these forward-looking statements, except as required by applicable law.
CONTACTS:
Investor Relations contacts
Corey Davis, Ph.D.
LifeSci Advisors, LLC
Cdavis@lifesciadvisors.com
P: (212) 915-2577
